Related Experiment Video
Updated: Jun 7, 2025
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
Escitalopram Relieves Sleep Anxiety in Patients with Cerebral Small Vessel Disease Sleep Disorder by Downregulating
Lifei Xing1, Lihua Sun2, Hongliang Yan1
1Department of Neurology, Third Clinical Hospital (National Pharmaceutical North Hospital) of Baotou Medical College, Baotou City, Hubei Province, China.
Objective:
Nrf2/ARE signaling pathway is reported to alleviate sleep anxiety in patients with sleep disorders. This study aimed at exploring the effect of escitalopram (ESC) on sleep anxiety in patients with cerebral small vessel disease (CSVD) and sleep disorder and its correlation with the Nrf2/ARE signaling pathway.
Methods:
In the present study, we enrolled 80 CSVD patients (disease group) and 40 healthy patients (control group) in our hospital. The CSVD patients were classified into ESC treatment group and conventional treatment group and administered ESC and diazepam, respectively. After treatment, the patients' sleep quality was monitored within three months, and their symptoms were evaluated. Additionally, a mouse model of CSVD was set up, and the rats received intragastric administration of low, moderate, and high dosage of ESC or thymoquinone. The morphology of nerve cells and cognitive functions in the rat hippocampus were seen. TUNEL staining was conducted to detect nerve cell apoptosis and RT-qPCR, and Western blot analyses determined the expression levels of Nrf2 and ARE.
Results:
Compared with conventional treatment group, the patients of ESC treatment group had shorter symptom improvement time and better sleep quality with a lower AHI and PSQI score. On the other hand, in the animal model, ESC treatment alleviated sleep disorders in CSVD rats, improved cognition and serum TNF-α levels, and protected nerve cells. Administration of ESC eliminated the expressions of Nrf2 and ARE and reduced nerve cell apoptosis dose-dependently. Moreover, Nrf2/ARE pathway activator (Danshensu) decreased rat sleep time and the level of serum TNF-α with more cell atrophy, while Nrf2/ARE pathway inhibitor (ML385) greatly improved sleep quality of CSVD rats.
Conclusion:
ESC can effectively relieve sleep anxiety in patients with CSVD and sleep disorders through downregulating the Nrf2/ARE signaling pathway. ESC treatment increases patient's sleep time and serum TNF-α levels and attenuates nerve cell damage, further improving the patient's sleep quality.
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
01:13Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
01:26Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...